$SE An exciting time for Sea Limited. I discuss existing AI investments and the path Sea is likely to take with Sea Cloud.
Read here: sleepwellinvestments.com/p/s…
$SE Shopee VIP + Netflix
August portfolio review - Cyber Security up huge...
$CRWD, $FTNT. Buys are up nearly 100% $PME, $VEEV
sleepwellinvestments.com/p/s…
$WTC.AX Wisetech's investment thesis is now a ‘special situation’.
I was wrong to catch the falling knife with my 3 additions on the decline. So, FY2026 results a few days ago provided vital information to set up a more methodological buy/sell plan going forward.
We will evaluate
(i) where the business stands after the corporate governance ordeal,
(ii) the e2open acquisition,
(iii) the pricing model transition, and
(iv) AI prospects.
Read all here - sleepwellinvestments.com/p/w…
Post-Lugano $EYPT, $OCUL's peak sales and market share are likely higher, and bidders now have just ONE real option vs 2 previously. I'm hopeful for a higher acquisition price now, and bids may come at any time until the NDA acceptance date.
Both HELIOS-3 (DR, once-yearly dosing) and AXPAXLI’s potential wAMD approval are lined up for roughly the same window in H2 2027. That’s when $OCUL can go stratospheric and serious M&A interest shows up.
@birgirm80 @Biomaven @AscendingBio @RazBioTech @zipjet @JeremyFalmouth @semodough what do you think? $EYPT and $OCUL bears' thoughts?
$PME.AX The question everyone asks: Will AI disrupt PME?
Wrong question.
The right one: Who controls access to AI in radiology?
Every algorithm — PME-built, co-developed with NYU, or third-party like EchoIQ — must integrate through the Visage 7 viewer to reach 11% of US radiology.
PME isn't the disrupted. It's the gate.
Full FY2026 review is live on Sleep Well Investments.
I cover:
→ Why forward growth is likely 30%+ despite 24% topline
→ Key-man risk update (and why 2% staff turnover matters)
→ The AI playbook in full: NYU breast cancer, EchoIQ, the new reporting module
→ The premium valuation — can it hold?
One of the best businesses I own. $PME.AX
sleepwellinvestments.com/p/p…
$CLBT had time to review the Q2 miss; full-year 2026 ARR fell by $15M due to execution mishaps; shares are now 30% cheaper, but the valuation isn't screaming cheap yet.
Read the full review here sleepwellinvestments.com/p/c…
$CLBT Longer sales cycles and less expansion from Inseyets conversions than anticipated. Guidance cut; CEO Tom Hogan 'fired'... shares down 30% pre-market, fair?
$CLBT Longer sales cycles and less expansion from Inseyets conversions than anticipated. Guidance cut; CEO Tom Hogan 'fired'... shares down 30% pre-market, fair?
Sleep Well Investments retweeted
Enjoy this FREE analysis of $SE Sea Limited Q2’26 results.
I discuss Shopee margin potential; VIP and Livestream excelled; Monee's controlled expansion; Garena steady.
SE is now 55% of my PA.
Read here sleepwellinvestments.com/p/s…















